Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, an expert medical oncology panel, led by Elizabeth R. Plimack, MD, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses current best practices for the second-line treatment and beyond of patients with metastatic renal cell carcinoma (RCC). Topics include:
Content based on an online CME program supported by an educational grant from Eisai, Exelixis, and Pfizer and EMD Serono.Link to full program: https://www.clinicaloptions.com/oncology/programs/rcc-immuno-oncology
Commentary from Nelson F. Sanchez, MD, on caring for transgender individuals, from the healthcare disparities they face to how healthcare professionals can improve their care, from Clinical Care Options (CCO)
Experts describe key takeaways from a live symposium on HER2-, HER3-, and TROP2-targeted therapies and treatment approaches for patients, from Clinical Care Options (CCO)
Downloadable slideset from Eric Jonasch, MD on managing treatment-related adverse events for patients with RCC, from Clinical Care Options (CCO).
Downloadable slideset from Katy E. Beckermann, MD, PhD on the selection and sequencing of therapy for patients with advanced RCC after progression on first-line therapy, from Clinical Care Options (CCO).